These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 19542537)

  • 1. CK2-dependent phosphorylation determines cellular localization and stability of ataxin-3.
    Mueller T; Breuer P; Schmitt I; Walter J; Evert BO; Wüllner U
    Hum Mol Genet; 2009 Sep; 18(17):3334-43. PubMed ID: 19542537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteotoxic stress increases nuclear localization of ataxin-3.
    Reina CP; Zhong X; Pittman RN
    Hum Mol Genet; 2010 Jan; 19(2):235-49. PubMed ID: 19843543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Casein kinase 2 interacts with and phosphorylates ataxin-3.
    Tao RS; Fei EK; Ying Z; Wang HF; Wang GH
    Neurosci Bull; 2008 Oct; 24(5):271-7. PubMed ID: 18839019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ataxin-3 protein modification as a treatment strategy for spinocerebellar ataxia type 3: removal of the CAG containing exon.
    Evers MM; Tran HD; Zalachoras I; Pepers BA; Meijer OC; den Dunnen JT; van Ommen GJ; Aartsma-Rus A; van Roon-Mom WM
    Neurobiol Dis; 2013 Oct; 58():49-56. PubMed ID: 23659897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Polyglutamine-expanded ataxin-3 is degraded by autophagy].
    Xiao H; Tang J; Hu Z; Tan J; Tang B; Jiang Z
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2010 Feb; 27(1):23-8. PubMed ID: 20140862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FOXO4-dependent upregulation of superoxide dismutase-2 in response to oxidative stress is impaired in spinocerebellar ataxia type 3.
    Araujo J; Breuer P; Dieringer S; Krauss S; Dorn S; Zimmermann K; Pfeifer A; Klockgether T; Wuellner U; Evert BO
    Hum Mol Genet; 2011 Aug; 20(15):2928-41. PubMed ID: 21536589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Flanking domain stability modulates the aggregation kinetics of a polyglutamine disease protein.
    Saunders HM; Gilis D; Rooman M; Dehouck Y; Robertson AL; Bottomley SP
    Protein Sci; 2011 Oct; 20(10):1675-81. PubMed ID: 21780213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inactivation of PNKP by mutant ATXN3 triggers apoptosis by activating the DNA damage-response pathway in SCA3.
    Gao R; Liu Y; Silva-Fernandes A; Fang X; Paulucci-Holthauzen A; Chatterjee A; Zhang HL; Matsuura T; Choudhary S; Ashizawa T; Koeppen AH; Maciel P; Hazra TK; Sarkar PS
    PLoS Genet; 2015 Jan; 11(1):e1004834. PubMed ID: 25590633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proteolytic cleavage of polyglutamine-expanded ataxin-3 is critical for aggregation and sequestration of non-expanded ataxin-3.
    Haacke A; Broadley SA; Boteva R; Tzvetkov N; Hartl FU; Breuer P
    Hum Mol Genet; 2006 Feb; 15(4):555-68. PubMed ID: 16407371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Recent advances in molecular genetics of spinocerebellar ataxia type 3/Machado-Joseph disease].
    Jia D; Jiang H; Tang B
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Dec; 25(6):660-2. PubMed ID: 19065526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo suppression of polyglutamine neurotoxicity by C-terminus of Hsp70-interacting protein (CHIP) supports an aggregation model of pathogenesis.
    Williams AJ; Knutson TM; Colomer Gould VF; Paulson HL
    Neurobiol Dis; 2009 Mar; 33(3):342-53. PubMed ID: 19084066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nuclear localization of ataxin-3 is required for the manifestation of symptoms in SCA3: in vivo evidence.
    Bichelmeier U; Schmidt T; Hübener J; Boy J; Rüttiger L; Häbig K; Poths S; Bonin M; Knipper M; Schmidt WJ; Wilbertz J; Wolburg H; Laccone F; Riess O
    J Neurosci; 2007 Jul; 27(28):7418-28. PubMed ID: 17626202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Calpain-mediated ataxin-3 cleavage in the molecular pathogenesis of spinocerebellar ataxia type 3 (SCA3).
    Hübener J; Weber JJ; Richter C; Honold L; Weiss A; Murad F; Breuer P; Wüllner U; Bellstedt P; Paquet-Durand F; Takano J; Saido TC; Riess O; Nguyen HP
    Hum Mol Genet; 2013 Feb; 22(3):508-18. PubMed ID: 23100324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of spinocerebellar ataxia type 3 mouse models identifies early gain-of-function, cell-autonomous transcriptional changes in oligodendrocytes.
    Ramani B; Panwar B; Moore LR; Wang B; Huang R; Guan Y; Paulson HL
    Hum Mol Genet; 2017 Sep; 26(17):3362-3374. PubMed ID: 28854700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toward understanding Machado-Joseph disease.
    Costa Mdo C; Paulson HL
    Prog Neurobiol; 2012 May; 97(2):239-57. PubMed ID: 22133674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of the mammalian DNA end-processing enzyme polynucleotide kinase 3'-phosphatase in spinocerebellar ataxia type 3 pathogenesis.
    Chatterjee A; Saha S; Chakraborty A; Silva-Fernandes A; Mandal SM; Neves-Carvalho A; Liu Y; Pandita RK; Hegde ML; Hegde PM; Boldogh I; Ashizawa T; Koeppen AH; Pandita TK; Maciel P; Sarkar PS; Hazra TK
    PLoS Genet; 2015 Jan; 11(1):e1004749. PubMed ID: 25633985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ataxin-3 is translocated into the nucleus for the formation of intranuclear inclusions in normal and Machado-Joseph disease brains.
    Fujigasaki H; Uchihara T; Koyano S; Iwabuchi K; Yagishita S; Makifuchi T; Nakamura A; Ishida K; Toru S; Hirai S; Ishikawa K; Tanabe T; Mizusawa H
    Exp Neurol; 2000 Oct; 165(2):248-56. PubMed ID: 10993685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence for proteasome involvement in polyglutamine disease: localization to nuclear inclusions in SCA3/MJD and suppression of polyglutamine aggregation in vitro.
    Chai Y; Koppenhafer SL; Shoesmith SJ; Perez MK; Paulson HL
    Hum Mol Genet; 1999 Apr; 8(4):673-82. PubMed ID: 10072437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Druggable genome screen identifies new regulators of the abundance and toxicity of ATXN3, the Spinocerebellar Ataxia type 3 disease protein.
    Ashraf NS; Sutton JR; Yang Y; Ranxhi B; Libohova K; Shaw ED; Barget AJ; Todi SV; Paulson HL; Costa MDC
    Neurobiol Dis; 2020 Apr; 137():104697. PubMed ID: 31783119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Silencing mutant ATXN3 expression resolves molecular phenotypes in SCA3 transgenic mice.
    Rodríguez-Lebrón E; Costa Mdo C; Luna-Cancalon K; Peron TM; Fischer S; Boudreau RL; Davidson BL; Paulson HL
    Mol Ther; 2013 Oct; 21(10):1909-18. PubMed ID: 23820820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.